The exogenous anti-CD27 stimulation has demonstrated preferential adjuvant effects for peptide vaccines containing linked class-I/II epitopes and was more effective in amplifying antigen-specific CD8+T-cell responses in a CD4+helper-dependent manner, displaying anti-tumor efficacy in intracranial melanoma models [176]. Here, CD27 is linked to neoplasm.